首页 > 市场调查报告书 > 製药

生物製剂分子标靶治疗学

市场调查报告书

商品编码

1481761

全球 HER2 抗体市场研究报告 - 2024 年至 2032 年产业分析、规模、份额、成长、趋势与预测

Global HER2 Antibodies Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年05月01日 | 出版商:

Value Market Research | 英文 117 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

预计到 2032 年，全球 HER2 抗体市场需求将从 2023 年的 100.2 亿美元达到近 170.7 亿美元的市场规模，2024-2032 年研究期间复合年增长率为 6.1%。

HER2 抗体构成了一种用于治疗 HER2 阳性乳癌的标靶治疗形式，HER2 阳性乳癌是一种乳癌亚型，其特征是人类表皮生长因子受体 2 (HER2) 蛋白过度表现。这些抗体与癌细胞上的 HER2 受体结合，阻断其讯号传导路径并抑制细胞生长和增殖。透过专门针对 HER2 阳性癌细胞，这些抗体有助于选择性杀死癌细胞，同时不伤害正常细胞，从而最大限度地减少副作用。 HER2 抗体疗法通常与化疗或其他标靶疗法合併使用，以改善 HER2 阳性乳癌患者的治疗结果和存活率。

市场动态

HER2 阳性乳癌（一种以 HER2 蛋白过度表现为特征的乳癌亚型）的盛行率不断上升，正在推动对 HER2 抗体等标靶治疗的需求。 HER2 阳性乳癌在全球乳癌病例中占很大比例，因此需要开发有效的治疗方案来改善患者的预后。此外，分子诊断和生物标记测试的进步使医疗保健提供者能够检测出可能受益于 HER2 标靶治疗的患者，进一步推动市场成长。此外，引入具有改进的功效、安全性和耐受性的新型 HER2 抗体可以扩大 HER2 阳性乳癌患者的治疗选择，从而推动市场成长。

此外，製药公司、研究机构和医疗机构之间的合作推动了 HER2 抗体开发的创新，从而发现了新的治疗标靶和联合疗法。此外，支持使用 HER2 抗体治疗乳癌的监管批准和报销政策正在推动市场扩张和可及性。然而，标靶治疗和替代治疗方案的进步可能会挑战未来几年的市场成长。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具也对全球 HER2 抗体市场的各个细分市场进行了包容性评估。 HER2 抗体产业的成长和趋势为本研究提供了整体方法。

市场区隔

HER2 抗体市场报告的这一部分提供了国家和区域层面细分市场的详细资料，从而帮助策略师确定相应产品或服务的目标人群以及即将到来的机会。

按治疗药物

曲妥珠单抗
拉帕替尼
阿多曲妥珠单抗 Emtansine
帕妥珠单抗
依维莫司

区域分析

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲 HER2 抗体市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。 HER2抗体市场的主要参与者包括诺华公司、辉瑞、F. Hoffmann-La Roche Ltd.、Abnova Corporation、InvivoGen、Celltrion Inc.、Biocon、Novus Biologicals。本节包含竞争格局的整体视图，包括各种策略发展，例如关键併购、未来产能、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

区域展望
介绍
北美销售分析
- 概览、历史与预测资料销售分析
- 北美按细分市场销售分析
- 北美按国家销售分析
- 美国销售分析
- 加拿大销售分析
- 墨西哥销售分析
欧洲销售分析
- 概览、历史与预测资料销售分析
- 欧洲按细分市场销售分析
- 欧洲按国家销售分析
- 英国销售分析
- 法国销售分析
- 德国销售分析
- 义大利销售分析
- 俄罗斯销售分析
- 欧洲其他地区销售分析
亚太地区销售分析
- 概览、历史与预测资料销售分析
- 亚太地区按细分市场销售分析
- 亚太地区按国家销售分析
- 中国销售分析
- 印度销售分析
- 日本销售分析
- 韩国销售分析
- 澳洲销售分析
- 东南亚销售分析
- 亚太地区其他地区销售分析
拉丁美洲销售分析
- 概览、历史与预测资料销售分析
- 拉丁美洲按细分市场销售分析
- 拉丁美洲按国家销售分析
- 巴西销售分析
- 阿根廷销售分析
- 秘鲁销售分析
- 智利销售分析
- 拉丁美洲其他地区销售分析
中东和非洲销售分析
- 概览、历史与预测资料销售分析
- 中东和非洲按细分市场销售分析
- 中东和非洲按国家销售分析
- 沙乌地阿拉伯销售分析
- 阿联酋销售分析
- 以色列销售分析
- 南非销售分析
- 中东其他地区和非洲销售分析

第 7 章：HER2 抗体公司的竞争格局

HER2抗体市场竞争
伙伴关係/协作/协议
併购
新产品发布
其他发展

第 8 章：公司简介

顶级公司市占率分析
市场集中度
Novartis AG

公司简介
公司收入
产品
最近的发展

Pfizer Inc.

公司简介
公司收入
产品
最近的发展

F. Hoffmann-La Roche Ltd.

公司简介
公司收入
产品
最近的发展

Abnova Corporation

公司简介
公司收入
产品
最近的发展

InvivoGen

公司简介
公司收入
产品
最近的发展

Celltrion Inc.

公司简介
公司收入
产品
最近的发展

Biocon

公司简介
公司收入
产品
最近的发展

Novus Biologicals

公司简介
公司收入
产品
最近的发展

註 - 在公司概况中，财务详细资料和最新进展视情况而定，或对私人公司而言可能不包括在内

简介目录图表

Product Code: VMR112114433

The global demand for HER2 Antibodies Market is presumed to reach the market size of nearly USD 17.07 Billion by 2032 from USD 10.02 Billion in 2023 with a CAGR of 6.1% under the study period 2024-2032.

HER2 antibodies constitute a form of targeted therapy employed in treating HER2-positive breast cancer, a breast cancer subtype characterized by the overexpression of the human epidermal growth factor receptor 2 (HER2) protein. These antibodies bind to the HER2 receptors on cancer cells, blocking their signaling pathways and inhibiting cell growth and proliferation. By targeting HER2-positive cancer cells specifically, these antibodies help to selectively kill cancer cells while sparing normal cells, minimizing side effects. HER2 antibody therapies are often used in combination with chemotherapy or other targeted therapies to improve treatment outcomes & survival rates among patients with HER2-positive breast cancer.

MARKET DYNAMICS

The increasing prevalence of HER2-positive breast cancer, a subtype of breast cancer featured by overexpression of the HER2 protein, is driving demand for targeted therapies such as HER2 antibodies. HER2-positive breast cancer accounts for a significant proportion of breast cancer cases globally, necessitating the development of effective treatment options to improve patient outcomes. Additionally, advancements in molecular diagnostics and biomarker testing have enabled healthcare providers to detect patients likely to benefit from HER2-targeted therapies, further driving market growth. Moreover, introducing novel HER2 antibodies with improved efficacy, safety, and tolerability profiles expands treatment options for patients with HER2-positive breast cancer, driving market growth.

Furthermore, collaborations between pharmaceutical companies, research institutions, and healthcare organizations drive innovation in HER2 antibody development, resulting in the discovery of new therapeutic targets and combination therapies. Additionally, regulatory approvals and reimbursement policies supporting the use of HER2 antibodies in treating breast cancer are driving market expansion and accessibility. However, advancements in targeted therapies and alternative treatment options may challenge the market growth in the coming years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of HER2 Antibodies. The growth and trends of HER2 Antibodies industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the HER2 Antibodies market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Treatment Drugs

Trastuzumab
Lapatinib
Ado-trastuzumab Emtansine
Pertuzumab
Everolimus

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the HER2 Antibodies market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the HER2 Antibodies market include Novartis AG, Pfizer Inc., F. Hoffmann-La Roche Ltd., Abnova Corporation, InvivoGen, Celltrion Inc., Biocon, Novus Biologicals. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. HER2 ANTIBODIES - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Treatment Drugs
- 3.7.2 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL HER2 ANTIBODIES MARKET ANALYSIS BY TREATMENT DRUGS

5.1. Overview By Treatment Drugs
5.2. Historical and Forecast Data
5.3. Analysis By Treatment Drugs
5.4. Trastuzumab Historic and Forecast Sales By Regions
5.5. Lapatinib Historic and Forecast Sales By Regions
5.6. Ado-trastuzumab Emtansine Historic and Forecast Sales By Regions
5.7. Pertuzumab Historic and Forecast Sales By Regions
5.8. Everolimus Historic and Forecast Sales By Regions

6. GLOBAL HER2 ANTIBODIES MARKET ANALYSIS BY GEOGRAPHY

6.1. Regional Outlook
6.2. Introduction
6.3. North America Sales Analysis
- 6.3.1 Overview, Historic and Forecast Data Sales Analysis
- 6.3.2 North America By Segment Sales Analysis
- 6.3.3 North America By Country Sales Analysis
- 6.3.4 United States Sales Analysis
- 6.3.5 Canada Sales Analysis
- 6.3.6 Mexico Sales Analysis
6.4. Europe Sales Analysis
- 6.4.1 Overview, Historic and Forecast Data Sales Analysis
- 6.4.2 Europe By Segment Sales Analysis
- 6.4.3 Europe By Country Sales Analysis
- 6.4.4 United Kingdom Sales Analysis
- 6.4.5 France Sales Analysis
- 6.4.6 Germany Sales Analysis
- 6.4.7 Italy Sales Analysis
- 6.4.8 Russia Sales Analysis
- 6.4.9 Rest Of Europe Sales Analysis
6.5. Asia Pacific Sales Analysis
- 6.5.1 Overview, Historic and Forecast Data Sales Analysis
- 6.5.2 Asia Pacific By Segment Sales Analysis
- 6.5.3 Asia Pacific By Country Sales Analysis
- 6.5.4 China Sales Analysis
- 6.5.5 India Sales Analysis
- 6.5.6 Japan Sales Analysis
- 6.5.7 South Korea Sales Analysis
- 6.5.8 Australia Sales Analysis
- 6.5.9 South East Asia Sales Analysis
- 6.5.10 Rest Of Asia Pacific Sales Analysis
6.6. Latin America Sales Analysis
- 6.6.1 Overview, Historic and Forecast Data Sales Analysis
- 6.6.2 Latin America By Segment Sales Analysis
- 6.6.3 Latin America By Country Sales Analysis
- 6.6.4 Brazil Sales Analysis
- 6.6.5 Argentina Sales Analysis
- 6.6.6 Peru Sales Analysis
- 6.6.7 Chile Sales Analysis
- 6.6.8 Rest of Latin America Sales Analysis
6.7. Middle East & Africa Sales Analysis
- 6.7.1 Overview, Historic and Forecast Data Sales Analysis
- 6.7.2 Middle East & Africa By Segment Sales Analysis
- 6.7.3 Middle East & Africa By Country Sales Analysis
- 6.7.4 Saudi Arabia Sales Analysis
- 6.7.5 UAE Sales Analysis
- 6.7.6 Israel Sales Analysis
- 6.7.7 South Africa Sales Analysis
- 6.7.8 Rest Of Middle East And Africa Sales Analysis

7. COMPETITIVE LANDSCAPE OF THE HER2 ANTIBODIES COMPANIES

7.1. HER2 Antibodies Market Competition
7.2. Partnership/Collaboration/Agreement
7.3. Merger And Acquisitions
7.4. New Product Launch
7.5. Other Developments

8. COMPANY PROFILES OF HER2 ANTIBODIES INDUSTRY

8.1. Top Companies Market Share Analysis
8.2. Market Concentration Rate
8.3. Novartis AG
- 8.3.1 Company Overview
- 8.3.2 Company Revenue
- 8.3.3 Products
- 8.3.4 Recent Developments
8.4. Pfizer Inc.
- 8.4.1 Company Overview
- 8.4.2 Company Revenue
- 8.4.3 Products
- 8.4.4 Recent Developments
8.5. F. Hoffmann-La Roche Ltd.
- 8.5.1 Company Overview
- 8.5.2 Company Revenue
- 8.5.3 Products
- 8.5.4 Recent Developments
8.6. Abnova Corporation
- 8.6.1 Company Overview
- 8.6.2 Company Revenue
- 8.6.3 Products
- 8.6.4 Recent Developments
8.7. InvivoGen
- 8.7.1 Company Overview
- 8.7.2 Company Revenue
- 8.7.3 Products
- 8.7.4 Recent Developments
8.8. Celltrion Inc.
- 8.8.1 Company Overview
- 8.8.2 Company Revenue
- 8.8.3 Products
- 8.8.4 Recent Developments
8.9. Biocon
- 8.9.1 Company Overview
- 8.9.2 Company Revenue
- 8.9.3 Products
- 8.9.4 Recent Developments
8.10. Novus Biologicals
- 8.10.1 Company Overview
- 8.10.2 Company Revenue
- 8.10.3 Products
- 8.10.4 Recent Developments